COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children

COG NCTN 儿童造血系统恶性肿瘤综合转化科学中心

• 批准号: 10600096
• 负责人: SOHEIL MESHINCHI
• 金额: $ 53.53万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10600096
• 关键词: Acceleration; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute Promyelocytic Leukemia; Address; Adult; Area; B-Lymphocytes; Biological; Biological Markers; Biological Sciences; Biology; Cancer Biology; Cancer Etiology; Cancer Survivor; Cause of Death; Center for Translational Science Activities; Child; Child Care; Child Support; Childhood; Childhood Leukemia; Childhood Lymphoma; Classification; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Cytotoxic Chemotherapy; Data; Developmental Therapeutics Program; Diagnostic; Disease; Elements; Ensure; Eosinophilic Granuloma; Evaluation; Fostering; Funding; Generations; Genomic approach; Genomics; Goals; Grant; Guidelines; Hematologic Neoplasms; Hematopoietic; Hematopoietic Neoplasms; Heterogeneity; Hodgkin Disease; Infrastructure; Intervention; Juvenile Myelomonocytic Leukemia; Laboratories; Leadership; Link; Malignant Childhood Neoplasm; Malignant Neoplasms; Microscopy; Molecular; Morphology; Multi-Institutional Clinical Trial; Non-Hodgkin' s Lymphoma; North America; Outcome; Patients; Pediatric Neoplasm; Pediatric Oncology Group; Phase; Pilot Projects; Quality of life; Relapse; Research; Research Project Grants; Resources; Risk; Solid; Structure; Survivors; T-Lymphocyte; Therapeutic; Therapeutic Intervention; Therapeutic Trials; Therapeutic Uses; Translating; Translational Research; Translations; Treatment Efficacy; Validation; Variant; childhood cancer mortality; clinical application; clinical implementation; clinical practice; clinically actionable; clinically relevant; design; epigenomics; fundamental research; improved; improved outcome; innovation; leukemia/lymphoma; molecular diagnostics; molecular marker; new therapeutic target; novel; novel marker; operation; outcome prediction; personalized approach; pre-clinical; prevent; programs; prospective; research study; risk stratification; statistics; success; targeted treatment; therapeutic development; therapeutic target; young adult

Project Summary Hematopoietic malignancies including leukemias and lymphomas contribute to nearly half of all cancers and are a major cause of death from disease in children. The Children’s Oncology Group (COG) has spearheaded efforts to improve outcome in children with cancer, and despite dramatic improvements in survival over the last several decades, relapse remains a major problem, and survivors may suffer long term complications from the cytotoxic therapy. Better understanding of the biology of malignancies allows for more rational, targeted approaches to therapy, minimizing the need or the intensity of the non-selective cytotoxic therapies. Such targeted approaches have transformed some diseases from uniformly fatal to highly curable ones (e.g., CML, APL), but a paucity of actionable targets has prevented broader application of targeted interventions in hematopietic malignancies. As part of its focus on optimizing the survival in pediatric cancers and improving quality of life for the cancer survivors, COG through partnerships with NCI has conducted a number of discovery phase studies to identify the biologic basis of cancer in children, with the goal of identifying specific targets for more appropriate risk stratification and directed therapies in its clinical trials. With the emerging data from pediatric (and adult) discovery phase studies, COG is poised to take the next step in identifying actionable targets for therapeutic intervention. As part of these efforts, COG has created the Network Group Integrated Translational Science Centers (ITSCs) aimed at providing resources for therapeutically driven translational research. COG Hematopoietic ITSC (HM-ITSC) has put into place intellectual (leadership) and physical resources (resource laboratories, biospecimens, etc.) to ensure rapid identification of actionable targets through carefully designed translational research projects, and fostering the experimental data through a carefully structured mechanism to clinical application. HM-ITSC is structured and integrated into the functional operations of the COG, with direct links to the COG Operations Office, Disease Committees, Network group Data and Statistics Center and Developmental Therapeutics in order to facilitate rapid flow of actionable translational biology data to clinical implementation within NCTN clinical trials. Hematopoietic Malignancies (HM) are a major cause of cancer in children and novel therapeutic targets are needed to optimize outcome. COG HM-Integrated Translational Science Center, integrated into the functional organization of COG, will provide resources to support translational research in pediatric leukemias and lymphomas towards identification of clinically meaningful targets and their incorporation into clinical trials.

项目摘要 包括白血病和淋巴瘤在内的造血恶性肿瘤几乎有助于所有癌症和 是儿童疾病死亡的主要原因。儿童肿瘤学小组（COG）率先 努力改善癌症儿童的结果，并在最后的生存中急剧改善 几十年来，继电器仍然是一个主要问题，生存可能会遭受长期并发症 细胞毒性疗法。对恶性生物学的更好理解可以使更多理性，有针对性 治疗方法，最大程度地减少非选择性细胞毒性疗法的需求或强度。这样的 有针对性的方法已将某些疾病从统一致命的疾病转变为高度可治愈的疾病（例如，CML， apl），但是缺乏可行的目标已经阻止了在 造血恶性肿瘤。作为其专注于优化儿科癌症生存并改善的一部分 癌症存活的生活质量，通过与NCI的合作伙伴关系进行了许多 发现阶段研究以识别儿童癌症的生物学基础，目的是确定特定 在其临床试验中进行更适当的风险分层和定向疗法的目标。随着新兴数据 从小儿（和成人）发现阶段研究中，COG被毒死以迈出下一步确定可起诉的 治疗干预的目标。作为这些努力的一部分，COG创建了网络组集成 翻译科学中心（ITSC）旨在为治疗驱动的翻译提供资源 研究。 COG造血ITSC（HM-ITSC）已成为智力（领导力）和身体 资源（资源实验室，生物测量等），以确保快速确定可行的目标 通过精心设计的翻译研究项目，并通过 精心结构的临床应用机制。 HM-ITSC结构化并集成到功能中 COG的操作，直接链接到COG运营办公室，疾病委员会，网络组 数据和统计中心和发育疗法，以促进可行的快速流动 转化生物学数据到NCTN临床试验中的临床实施。造血恶性肿瘤 （HM）是儿童癌症的主要原因，需要新的治疗靶标才能优化预后。 COG HM集成的转化科学中心集成到COG的功能组织中，将 提供资源来支持小儿白血病和淋巴瘤的转化研究 将临床意义的目标及其工业识别为临床试验。